KRAS and non-small cell lung carcinoma: KRAS amplification was implicated as the mechanism of resistance from crizotinib treatment in MET exon 14 mutant-NSCLC in a study using patient tumor-derived cells and xenografts, which was effectively targeted by dual MET/PI3K inhibition (42).